4-(4-(4-methyl-3-(thiazol-2-yl)phenyl)phthalazin-1-ylamino)benzenesulfonamide

ID: ALA5182554

Chembl Id: CHEMBL5182554

PubChem CID: 168278414

Max Phase: Preclinical

Molecular Formula: C24H19N5O2S2

Molecular Weight: 473.58

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccc(-c2nnc(Nc3ccc(S(N)(=O)=O)cc3)c3ccccc23)cc1-c1nccs1

Standard InChI:  InChI=1S/C24H19N5O2S2/c1-15-6-7-16(14-21(15)24-26-12-13-32-24)22-19-4-2-3-5-20(19)23(29-28-22)27-17-8-10-18(11-9-17)33(25,30)31/h2-14H,1H3,(H,27,29)(H2,25,30,31)

Standard InChI Key:  QOLXCXJVCNMSMN-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5182554

    ---

Associated Targets(Human)

ENPP3 Tchem Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (241 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA9 Tclin Carbonic anhydrase IX (8255 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 473.58Molecular Weight (Monoisotopic): 473.0980AlogP: 5.12#Rotatable Bonds: 5
Polar Surface Area: 110.86Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.74CX Basic pKa: 3.15CX LogP: 4.64CX LogD: 4.64
Aromatic Rings: 5Heavy Atoms: 33QED Weighted: 0.37Np Likeness Score: -1.60

References

1. Lee SY, Namasivayam V, Boshta NM, Perotti A, Mirza S, Bua S, Supuran CT, Müller CE..  (2021)  Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.,  12  (7.0): [PMID:34355184] [10.1039/D1MD00117E]

Source